Herein, using the TCGA database, we discovered that IGF2BP3 was significantly positively associated with the immune component of TME in 11 cancers, including BLCA, BRCA, COAD, KIRC, KIRP, LAML, LGG, PCPG, PRAD, READ, and UVM, negatively associated with the stromal component of TME in 4 cancers, including ACC, GBM, LUSC and UCEC (Figure 9). Here, IGF2BP3 is linked to cancer.